Announced Tue, 1 Sept, 2026 · 17:59 IST
Caplin Point subsidiary gets GMP certification from Colombia's INVIMA
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.4%1-day move
₹2713.60
prior close
₹2710.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.7-1.0-0.6-1.5+4.4+2.9+4.2+2.3-0.0+1.4+5.2-4.7——
Up moveDown movePending
AI summary
Caplin Point Laboratories' subsidiary Caplin One Labs (COL) has received GMP compliance certification from INVIMA, Colombia's drug regulator. The certification covers COL's manufacturing facility in Kakkalur, Tamil Nadu for oncology drug products including sterile lyophilized injection powder in vials, coated and uncoated tablets, and hard capsules. The formal certificate is expected shortly.
Likely market impact
Opens Colombian and potentially wider Latin American markets for the subsidiary's oncology drug portfolio, supporting future export growth.